Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals, Inc. (AVIR) Q2 2026 Earnings Call Transcript

Atea Pharmaceuticals Q2 Earnings Call Highlights

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026

Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus

Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026